US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Incyte Corporation (INCY)
Incyte Corporation (INCY) ニュース

INCY

Incyte (INCY)

Incyte Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/02	21 : 00	Business Wire	Incyte to Present at Upcoming Investor Conference	NASDAQ:INCY	Incyte Corporation
2024/04/30	20 : 00	Business Wire	Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	NASDAQ:INCY	Incyte Corporation
2024/04/24	07 : 11	Business Wire	Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie	NASDAQ:INCY	Incyte Corporation
2024/04/24	07 : 01	Business Wire	Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt	NASDAQ:INCY	Incyte Corporation
2024/04/23	20 : 00	Business Wire	Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	NASDAQ:INCY	Incyte Corporation
2024/04/11	21 : 00	Business Wire	Incyte to Report First Quarter Financial Results	NASDAQ:INCY	Incyte Corporation
2024/04/01	21 : 30	Business Wire	Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	NASDAQ:INCY	Incyte Corporation
2024/03/30	05 : 30	Business Wire	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:INCY	Incyte Corporation
2024/03/11	21 : 57	Business Wire	Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt	NASDAQ:INCY	Incyte Corporation
2024/03/11	21 : 57	Business Wire	Incyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modérée	NASDAQ:INCY	Incyte Corporation
2024/03/11	19 : 06	Business Wire	Incyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaire	NASDAQ:INCY	Incyte Corporation
2024/03/11	18 : 53	Business Wire	Incyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vor	NASDAQ:INCY	Incyte Corporation
2024/03/11	05 : 05	Business Wire	Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	NASDAQ:INCY	Incyte Corporation
2024/03/11	05 : 05	Business Wire	Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	NASDAQ:INCY	Incyte Corporation
2024/03/05	04 : 38	Business Wire	De nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)	NASDAQ:INCY	Incyte Corporation
2024/03/05	04 : 02	Business Wire	Neue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiert	NASDAQ:INCY	Incyte Corporation
2024/03/04	22 : 00	Business Wire	New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting	NASDAQ:INCY	Incyte Corporation
2024/03/01	00 : 19	Business Wire	Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI	NASDAQ:INCY	Incyte Corporation
2024/02/29	21 : 30	GlobeNewswire Inc.	Knight Therapeutics Announces Launch of Minjuvi® in Brazil	NASDAQ:INCY	Incyte Corporation
2024/02/28	23 : 11	Business Wire	Incyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôte	NASDAQ:INCY	Incyte Corporation
2024/02/28	21 : 15	Business Wire	Incyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hat	NASDAQ:INCY	Incyte Corporation
2024/02/28	06 : 08	Business Wire	Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease	NASDAQ:INCY	Incyte Corporation
2024/02/17	06 : 04	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:INCY	Incyte Corporation
2024/02/17	02 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/15	22 : 00	Business Wire	Incyte to Present at Upcoming Investor Conference	NASDAQ:INCY	Incyte Corporation

Showing the most relevant articles for your search:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 次へ >>

Deutsche Telekom (QX)

US Dollar vs Sterling

JP Morgan Chase

Gold vs US Dollar

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約